Jane Street Group, LLC Revance Therapeutics, Inc. Call Options Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $161,653 - $161,653	62,900 New	62,900 $161,000
Q1 2022 May 17, 2022	BUY	$12.36 - $20.31 $442,488 - $727,098	35,800 Added 45.09%	115,200 $2.25 Million
Q4 2021 Feb 15, 2022	BUY	$12.46 - $27.87 $752,584 - $1.68 Million	60,400 Added 317.89%	79,400 $1.3 Million
Q3 2021 Nov 16, 2021	SELL	$25.78 - $33.21 $1.32 Million - $1.7 Million	-51,200 Reduced 72.93%	19,000 $529,000
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $787,920 - $936,096	-29,400 Reduced 29.52%	70,200 $2.08 Million
Q1 2021 May 18, 2021	BUY	$24.03 - $29.97 $1.76 Million - $2.2 Million	73,300 Added 278.71%	99,600 $2.78 Million
Q4 2020 Feb 17, 2021	BUY	$23.41 - $28.34 $227,077 - $274,898	9,700 Added 58.43%	26,300 $745,000
Q3 2020 Nov 17, 2020	BUY	$23.23 - $34.3 $385,618 - $569,380	16,600 New	16,600 $417,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.